Sigyn Therapeutics Inc. (SIGYD) Completes Reverse Stock Split, Releases Year-End Financial Report for 2023
Sigyn's common stock, temporarily trading under the ticker symbol "SIGYD", is set to revert back to its historic symbol "SIGY" on February 29, 2024. The company, as part of its 2023 Year-End Report, summarized its development of medical technologies that target to overcome clearly defined limitations in global health. During 2023, Sigyn expanded its line-up of medical technologies designed to enhance the benefit of cancer therapies. The company’s cancer treatment pipeline now includes ImmunePrep(TM), ChemoPrep(TM), and ChemoPure(TM). The company believes the successful clinical advancement of Sigyn Therapy(TM) to treat pathogen-associated conditions beyond the reach of drugs, may offer a…
